Principal Investigators

    Stefan Ståhl


    KTH Royal Institute of Technology

    Contact information of lead PI



    Title of project or programme

    Sequestrins - New small protein drugs targeting neurodegenerative disorders

    Source of funding information

    The Swedish Brain Foundation

    Total sum awarded (Euro)

    € 108,814

    Start date of award


    Total duration of award in years



    Research Abstract

    This application is motivated by very positive and encouraging recent preclinical results (described below) from a novel therapeutic approach in the field of Alzheimer’s disease (AD). The overall objective is to explore how small affinity
    proteins can be utilized as new types of protein drugs for neurodegenerative disorders. Affinity proteins have indeed proven suitable for targeting applications, e.g. to detect cancer tumors, but also as capturing agents for blocking of
    protein:protein interactions and even to sequester proteins in the circulation. This proposal intends to explore a novel and challenging biotherapy strategy. Very small affinity proteins, termed sequestrins, that are developed in-house, will be
    investigated as in vivo capturing agents aimed towards future treatment of neurodegenerative disorders, with an initial focus on AD. A sequestrin is a new type of protein scaffold, based on head-to-tale-linked affibody molecules, aimed to act as
    “molecular tweezers” capturing aggregation-prone peptides and proteins.

    Further information available at:

Types: Investments < €500k
Member States: Sweden
Diseases: N/A
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF